Navigation Links
FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial
Date:3/9/2011

SEATTLE, March 10, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL") following discussions with the  U.S. Food and Drug Administration's (the "FDA") Division of Hematologic Products (the "DHP") .  The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy, utilizing progression free survival ("PFS") and Overall Survival ("OS")as co-primary endpoints of the study. The PIX-R trial, is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant. During its discussions with the DHP the Company was advised that only OS would be acceptable for a formal Special Protocol Assessment ("SPA") agreement, however the DHP noted that the Company could conduct a study utilizing PFS along with OS as co-primary endpoints which would be an acceptable design outside of the formal SPA process. Regulatory acceptability will depend on the magnitude of the difference between the trial study arms as well as a risk and benefit analysis.

"CTI has worked with the DHP since August on an appropriate clinical trial design that may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of an appeal of CTI's new drug application for pixantrone based on the PIX 301 trial at the FDA's Office of New Drugs," stated James A. Bianco, M.D., CEO of Cell Therapeutics.

"We believe that pre-clinical data and results from a randomized clinical trial have already demonstrated syn
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
2. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
3. Savient Pharmaceuticals Provides Business Update
4. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
5. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
7. Generex Provides Additional Details for October 21st Live Video Webcast
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
10. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
11. NeoStem Provides Second Quarter Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic ... expanded its myPROpad™ ePRO tablet with the addition of ... the most widely used and well-respected Patient Reported Outcome ... EQ-5D is used during clinical trials and in other ... be used to demonstrate Health-Related Quality of Life outcomes ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2
... bit proprietary about the companies that have launched products at the ... always sorry when a company hits the bumps that inevitably pock ... so many of my "children" see the rewards for their very ... on the fund-raising circuit. Jingle Networks (DEMOfall 05) has ...
... days of Marco Polo, if not well before. It started ... to finished products. Next came financial capital. In more recent ... have gone global. What's different today from the past is ... perceived opportunities are vast but there are downsides as well, ...
... after solidifying its global market position with a key acquisition, ... working capital as well. The company announced that it will ... sources. , ,Imago, a provider of atom probe tomography instruments ... with funding led by Draper Fisher Jurvetson (DFJ), ...
Cached Biology Technology:A windfall of funds for DEMO companies 2A windfall of funds for DEMO companies 3Learning to swim in the global talent pool 2Learning to swim in the global talent pool 3Learning to swim in the global talent pool 4Investors commit $3.4 million to Imago 2
(Date:8/20/2014)... MA Using population-based screening outcomes of approximately 3 ... including four researchers at the University of Massachusetts Medical ... immunodeficiency (SCID) can be successfully implemented across public health ... published in the Aug. 20 issue of the ... ) showed the rate of SCID in newborns is ...
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... forest, popularly known as the lungs of the planet, inhales ... from the air to grow parts that eventually fall to ... region,s plentiful rainfall. Until recently people believed much ... and ended up deep in the ocean. University of Washington ...
... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ...
... University of Bristol and published online today in the ... how the brain and inner ear developed in dinosaurs. ... Sciences, together with Tom Hbner from the Niederschsische Landesmuseum ... year old dinosaurs. The two palaeontologists studied different ...
Cached Biology News:Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2
TAR DNA binding protein...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
... sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental animals. ... minutes after turn-on. ... ... ...
Biology Products: